Adaptimmune Therapeutics PLC expected to post a loss of 10 cents a share - Earnings Preview

Adaptimmune Therapeutics

13/05/2024 14:09

* Adaptimmune Therapeutics PLC  ADAP.OQ   ADAP.O  is
expected
to show a fall in quarterly revenue when it reports  results on
May 15 for the period ending January 1 0001
    * The Abingdon Oxfordshire-based  company is expected to
report a
77.5% decrease in revenue to $10.733 million from $47.6 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Adaptimmune Therapeutics
PLC
is for a loss of 10 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $2.50​, above​ its last closing price
of $1.12. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.08       -0.10      -0.24     Missed  -140
 Sep. 30 2023  -0.12       -0.14      -0.20     Missed  -45.5
 Jun. 30 2023  -0.12       -0.13      -0.23     Missed  -72.8​
 Mar. 31 2023  -0.15       -0.15      0.01      Beat    104.1
 ​​Dec.        -0.25       -0.25      -0.18     Beat    27.5
 31 2022                                                
 Sep. 30 2022  -0.28       -0.24      -0.24     Met     0.7​
 Jan. 1 0001   -0.28       -0.25      -0.28     Missed  -14.2
 Mar. 31 2022  -0.24       -0.22      -0.30     Missed  -36.8
 This summary was machine generated May 13 at 13:09 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)